*Results on May 18*
Tata Motors, Canara Bank, Aarti Industries, Abbott India, Torrent Pharmaceuticals, Ujjivan Small Finance Bank, Arfin India, Astral, Biogen Pharmachem Industries, Brigade Enterprises, Century Enka, Chalet Hotels, Coromandel Engineering Company, Diamines & Chemicals, Dolat Investments, Ester Industries, GSK Pharma, Gujarat Alkalies & Chemicals, Gulshan Polyols, IIFL Wealth Management, JBM Auto, Jindal Stainless (Hisar), JSL Industries, Jyothy Labs, Kalyani Investment Company, Kalyani Steels, Minda Corporation, PI Industries, Pioneer Embroideries, Route Mobile, Shilp Gravures, Umang Dairies, Upsurge Investment & Finance, and Xtglobal Infotech will release quarterly earnings scorecard on May 18
Tata Motors, Canara Bank, Aarti Industries, Abbott India, Torrent Pharmaceuticals, Ujjivan Small Finance Bank, Arfin India, Astral, Biogen Pharmachem Industries, Brigade Enterprises, Century Enka, Chalet Hotels, Coromandel Engineering Company, Diamines & Chemicals, Dolat Investments, Ester Industries, GSK Pharma, Gujarat Alkalies & Chemicals, Gulshan Polyols, IIFL Wealth Management, JBM Auto, Jindal Stainless (Hisar), JSL Industries, Jyothy Labs, Kalyani Investment Company, Kalyani Steels, Minda Corporation, PI Industries, Pioneer Embroideries, Route Mobile, Shilp Gravures, Umang Dairies, Upsurge Investment & Finance, and Xtglobal Infotech will release quarterly earnings scorecard on May 18
Macquarie on Solara Pharma
Added to Asia Marquee Buy list
Catalyst: Vizag facility reaching optimal utilisation in 1QFY22, further clarity on Aurore merger synergy benefits
MS on AB Capital
OW, TP raised to Rs 158
PBT & PAT 19% & 30%, respectively, above MSe
Co seeing structural profitability expansion across biz
Conviction of it becoming a 15%+ annual compounder is rising; this, along with its parentage, make a potent combination for re-rating
CLSA on CIPLA
Weak quarter despite adjustments
Covid-19 products & monetisation of US inhaler pipeline key catalysts
Weak qtr with a miss across sales, Ebitda & net profit
Growth was rather muted across geographies
Raise 22-23CL EPS by 2-3%
CLSA on drreddys
Miss in 4Q but strong outlook
25% Ebitda margin goal achievable in 2-3yrs on sustainable basis (By FY24)
Strong performance in India, the EU and ROW & a steady quarter for the US
Raise our FY22/23CL EPS by 9%/15%
Escorts
CS: Demand bounceback in 2H + strong mid-term drivers of margin & market share gains
Medium-term strategy remains on track with focus on share gain in South, ramp up of capacity & boosting
exports through Kubota channel
Added to Asia Marquee Buy list
Catalyst: Vizag facility reaching optimal utilisation in 1QFY22, further clarity on Aurore merger synergy benefits
MS on AB Capital
OW, TP raised to Rs 158
PBT & PAT 19% & 30%, respectively, above MSe
Co seeing structural profitability expansion across biz
Conviction of it becoming a 15%+ annual compounder is rising; this, along with its parentage, make a potent combination for re-rating
CLSA on CIPLA
Weak quarter despite adjustments
Covid-19 products & monetisation of US inhaler pipeline key catalysts
Weak qtr with a miss across sales, Ebitda & net profit
Growth was rather muted across geographies
Raise 22-23CL EPS by 2-3%
CLSA on drreddys
Miss in 4Q but strong outlook
25% Ebitda margin goal achievable in 2-3yrs on sustainable basis (By FY24)
Strong performance in India, the EU and ROW & a steady quarter for the US
Raise our FY22/23CL EPS by 9%/15%
Escorts
CS: Demand bounceback in 2H + strong mid-term drivers of margin & market share gains
Medium-term strategy remains on track with focus on share gain in South, ramp up of capacity & boosting
exports through Kubota channel